Research Analysts Set Expectations for HRMY FY2025 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Equities research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Harmony Biosciences in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn $2.29 per share for the year, up from their previous forecast of $2.19. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share. Cantor Fitzgerald also issued estimates for Harmony Biosciences’ FY2026 earnings at $2.17 EPS.

Several other research firms have also recently commented on HRMY. Needham & Company LLC reiterated a “buy” rating and set a $49.00 price target on shares of Harmony Biosciences in a report on Tuesday, May 6th. UBS Group lowered their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a report on Monday, April 28th. The Goldman Sachs Group initiated coverage on shares of Harmony Biosciences in a report on Thursday, July 10th. They set a “neutral” rating and a $33.00 price target for the company. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $55.00 target price (up previously from $54.00) on shares of Harmony Biosciences in a report on Thursday, July 10th. Finally, Mizuho upped their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, May 15th. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Harmony Biosciences Trading Up 1.8%

NASDAQ HRMY opened at $34.80 on Monday. The company has a quick ratio of 3.80, a current ratio of 3.84 and a debt-to-equity ratio of 0.20. Harmony Biosciences has a 52 week low of $26.47 and a 52 week high of $41.61. The stock has a market capitalization of $2.00 billion, a PE ratio of 11.23, a price-to-earnings-growth ratio of 0.40 and a beta of 0.84. The firm has a 50 day moving average of $34.15 and a two-hundred day moving average of $33.75.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.78 by ($0.10). Harmony Biosciences had a return on equity of 26.34% and a net margin of 23.44%. The firm had revenue of $200.49 million for the quarter, compared to analyst estimates of $204.37 million. During the same quarter last year, the firm earned $1.05 EPS. The company’s revenue was up 16.0% on a year-over-year basis.

Institutional Trading of Harmony Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in Harmony Biosciences by 222.9% in the 1st quarter. GAMMA Investing LLC now owns 2,929 shares of the company’s stock valued at $97,000 after purchasing an additional 2,022 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Harmony Biosciences by 52.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 20,221 shares of the company’s stock valued at $671,000 after purchasing an additional 6,915 shares during the last quarter. Arizona State Retirement System raised its position in Harmony Biosciences by 6.4% in the 1st quarter. Arizona State Retirement System now owns 12,261 shares of the company’s stock valued at $407,000 after purchasing an additional 737 shares during the last quarter. Two Sigma Advisers LP raised its position in Harmony Biosciences by 21.8% in the 4th quarter. Two Sigma Advisers LP now owns 98,900 shares of the company’s stock valued at $3,403,000 after purchasing an additional 17,700 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Harmony Biosciences by 56.0% in the 1st quarter. SG Americas Securities LLC now owns 35,097 shares of the company’s stock valued at $1,165,000 after purchasing an additional 12,599 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.